BlackRock, Inc. 13D and 13G filings for BridgeBio Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 11:44 am Unchanged |
2024-09-30 | 13G | BridgeBio Pharma, Inc. BBIO |
BLACKROCK INC BLK |
12,878,839 6.800% |
0 (Unchanged) |
Filing |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | BridgeBio Pharma, Inc. BBIO |
BLACKROCK INC BLK |
12,878,839 6.800% |
2,722,066 (+26.80%) |
Filing |
| 2024-01-29 5:25 pm Purchase |
2023-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
BLACKROCK INC BLK |
10,156,773 5.800% |
322,372 (+3.28%) |
Filing |
| 2023-01-31 5:52 pm Purchase |
2022-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
BLACKROCK INC BLK |
9,834,401 6.600% |
558,811 (+6.02%) |
Filing |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
BLACKROCK INC BLK |
9,275,590 6.300% |
2,758,046 (+42.32%) |
Filing |
| 2021-02-05 07:51 am Purchase |
2020-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
BLACKROCK INC BLK |
6,517,544 5.300% |
6,517,544 (New Position) |
Filing |